Preliminary study on the construction of CAR-EGFR modified T cells (EGFR-CART) in hypopharyngeal squamous cell carcinoma
10.16066/j.1672-7002.2018.01.003
- VernacularTitle:下咽鳞状细胞癌CAR-EGFR修饰T细胞构建的初步研究
- Author:
Yang ZHANG
1
;
Yiming DING
;
Qi ZHONG
;
Xuejun CHEN
;
Pingdong LI
;
Jugao FANG
;
Xiaohong CHEN
;
Zhigang HUANG
Author Information
1. 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科
- Keywords:
Hypopharyngeal Neoplasms;
T-Lymphocytes;
Receptor;
Epidermal Growth Factor;
chimeric antigen receptor
- From:
Chinese Archives of Otolaryngology-Head and Neck Surgery
2018;25(1):17-21
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE Construct and validate the EGFR-CART (Epidermal growth factor receptor-chimeric antigen receptor T) cells targeting the Fadu cell line of hypopharyngeal squamous cell carcinoma, and provide the preclinical basis for the application of CART cell technology in hypopharyngeal squamous cell carcinoma. METHODS EGFR-CART cells and CART-control cells were constructed by lentivirus transfection. The expression of EGFR antibody in CART cells was detected by FACS fluorescence detection, and the expression of EGFR in Fadu cell line and HCT-116 cell line was verified. RESULTS EGFR-CART cells and CART-control cells were successfully constructed, the infection efficiency was about 67％, and there was no significant difference between the two groups in the distribution of cell subsets. HCT-116 is selected as the non target cells of EGFR-CART, Fadu as target cell. CONCLUSION In this study, we successfully prepared and validated the EGFR-CART cells targeting the Fadu cell line of hypopharyngeal squamous cell carcinoma, and laid the foundation for the application of CART technique in the treatment of hypopharyngeal carcinoma.
